Alnylam Pharmaceuticals, Inc. (ALNY) analyst actions
Rating and price-target actions on ALNY in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ALNY overview →
1 measured ALNY analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Alnylam Pharmaceuticals, Inc. (ALNY) And Encourages Shareholders to Reach Out | Press release | +0.16% | -0.51% |
Keep exploring
More ALNY: earnings → · SEC filings → · ALNY overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| ENDOCYTE (ECYT) | 671 | -0.08% | 46% |
| PolarityTE, Inc. (PTE) | 670 | -0.62% | 38% |
| UroGen Pharma Ltd. - Ordinary Shares (URGN) | 664 | +0.13% | 53% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 660 | 0.00% | 47% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.